[vc_row][vc_column][vc_column_text] [/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row][vc_row][vc_column width=»1/2″][vc_column_text] Oncomatryx at BIO 2016. June 6-9. San Francisco. If you are also attending Bio convention and would like to meet us please fill this form to arrange an appointment. [/vc_column_text][/vc_column][vc_column width=»1/2″][contact-form-7 id=»804″ title=»BIO appointment»][/vc_column][/vc_row]
Poster presentation at the 2nd ASPIC International Congress. 28-29 April, 2016. Porto. Portugal. We are pleased to inform you that Enrique De Alava team from Hospital Virgen del Rocío, Sevilla, Spain, will present the poster Targeting Ewing Sarcoma Cells and the tumor microenvironment with OMTX003 Anti-Endoglin Monoclonal Antibodies” at the ASPIC, with the results obtained from research work … Leer más
[vc_row][vc_column][vc_column_text][/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row][vc_row][vc_column width=»1/2″][vc_column_text] BIO-EUROPE Spring 2016. April 4-6, 2016. Stockholm, Sweden. Oral Presentation: “Tumor microenvironment – targeted biopharmaceuticals”. Laureano Simón, PhD If you are also attending Bio-Europe and would like to meet us please fill this form to arrange an appointment.[/vc_column_text][/vc_column][vc_column width=»1/2″][contact-form-7 id=»804″ title=»Meeting at BIO SPRING»][/vc_column][/vc_row]
6th World ADC Summit. 8th-10th February 2016. Berlin (Germany). ONCOMATRYX will be attending World ADC Berlin. Poster Presentation: “OMTX705, a powerful stroma-targeting ADC to treat invasive tumors” by Myriam Fabre, PhD. If you are also attending WORLD-ADC and would like to meet us please fill the form below to arrange an appointment. [contact-form-7 id=»804″ title=»CONGRESS appointment»]
10.12.2012 12:33 Uni Stuttgart und Oncomatrix starten Forschungskooperation Andrea Mayer-Grenu Abteilung Hochschulkommunikation Universität Stuttgart Neuer Krebsmedikamente für die Behandlung metastasierender Tumore Das spanische Biopharmazeutik-Unternehmen Oncomatrix und die Universität Stuttgart haben einen Forschungskooperationsvertrag abgeschlossen, um neue Immuntherapeutika mit spezifischer, tumorgerichteter Aktivität zu entwickeln, die minimale Nebenwirkungen auf gesundes Gewebe aufweisen sollen. Die im Baskenland ansässige Firma … Leer más
Spanish Company Oncomatrix Develops a Test That Detects Whether a Breast Cancer Disease Will Develop Metastasis 6/26/2013 9:28:31 AM Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!A Spanish Company Develops a Test That Detects Whether a Breast Cancer Disease Will Develop MetastasisDerio, 24 June 2013. The … Leer más
